RESUMO
The effect of 0.35 mg of norethisterone daily on cervical mucus and on urinary LH, pregnanediol and oestrogen levels was studied during two treatment cycles in five subjects who had been observed during a control cycle. Variable changes in hormone excretion patterns were found and are discussed.
PIP: The effects of .35 mg of norethisterone/day on cervical mucus and on urinary luteinizing hormone (LH), pregnanediol, and estrogen levels were studied during 2 treatment cycles in 5 healthy women who had been observed during a control cycle. LH was measured by radioimmunoassay, total estrogens by a semiautomatic rapid method, and pregnanediol by a gas chromatographic method. There was some effect on the LH excretion patte rn in all the treatment cycles. Pregnanediol levels suggested ovulation in 3 cycles. In all 3 of these cycles the LH peak was lower and not as pronounced as in the respective control cycles. A patient with some initial suppression of LH and estrogens became pregnant during the trial. Cervical mucus was scanty, thick, opaque, and impenetrable to sperm throughout treatment. Spotting occurred in 4 of the treatment cycles, 2 of which were ovulatory. 3 possible ways in which norethisterone might exert its contraceptive effect are listed.
Assuntos
Muco do Colo Uterino/efeitos dos fármacos , Estrogênios/urina , Hormônio Luteinizante/urina , Noretindrona/farmacologia , Pregnanodiol/urina , Feminino , Humanos , Noretindrona/administração & dosagemRESUMO
The urinary gonadotrophin and ovarian steroid excretion pattern was studied in five women taking an oral contraceptive formulation consisting of mestranol 50 mug and norethisterone 1 mg. Both the pretreatment and post-treatment cycles were normal. The ovulatory peak of luteinizing hormone (LH) during the treatment cycles was uniformly suppressed, but LH continued to be excreted within the normal range. In one fifth of the treatment cycles there was a pronounced and sustained rise of oestrogen output in the absence of ovulation, and in many of the other treatment cycles oestrogen levels suggested that active ovarian steroidogenesis was taking place.
